Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
⏰ React to the Market Faster with Custom, Real-Time News Get Started
BioInvent International BI-505 First Clinical Data Now Available
www.investing.com/analysis/bioinvent-international-bi-505-first-clinical-data-now-available-154013
BioInvent International BI-505 First Clinical Data Now Available
By Edison | Feb 05, 2013 11:48PM ET
The one into two at 10
January 2013 brought a clear safety and dose signal in the BI-505 Phase I for relapsed and refractory multiple myeloma (MM). In preclinical studies, BI-505 showed a tumour cell killing effect possibly by making myeloma cells susceptible to apoptosis. The Phase I was dose escalating with a safety end point. Interestingly but anecdotally, seven of 29 patients (24%) on extended dosing showed stable disease. BI-505 will progress to a small Phase IIa during 2013. BioInvent (BINV.ST) intends to partner BI-505
The one: BI-505 is crucial to current value
BI-505 is the remaining clinical programme from the January 2012 portfolio. Hence, gaining maximum value is important for investors. A deal by GenMab in August 2012 with J&J on a Phase I MM antibody, daratumumab, shows possible value. GenMab, a larger company, gained $55m upfront and $88m in equity with milestones and a 10%+ royalty. However, such Phase I deals are infrequent and BioInvent investors need to be prepared to fund BI-505 to add value by generating Phase II efficacy data.
Into two at 10: BI-505 progression to Phase II
BI-505 blocks the function of the cell surface adhesion molecule ICAM-1 (CD54). In the cancer literature, myeloid cells show cell-adhesion mediated drug resistance if attached to other cells. In BioInvent’s patent EP 2468775 (priority December 2006), ICAM blocking is claimed to cause apoptosis (cell suicide). The 35-patient dose escalation study in relapsed and refractory MM tested 11 dose stages of 0.0004mg/kg to 20mg/kg. BI-505 at 10mg/kg saturated the ICAM sites on bone marrow myeloma cells; this dose will be used for Phase II. Stable disease (based on M protein biomarker levels) was seen in 24% of the 29 patients who received extended dosing over 0.06mg/kg (level 6). The likelihood of success remains at 30%.
Valuation: Cash conservation to rebuild the portfolio
BioInvent had Q3 ytd cash of SEK153m with revenues of SEK 34m. Estimating year-end 2012 cash is difficult due to the actual H212 restructuring costs; SEK25-40m seems a probable range. The company needs to invest in BI-505, bring forward two other candidates into Phase I and support n-CoDeR. Operating cash costs in 2013 should be SEK75m. The small Phase IIa BI-505 study due to start sometime in 2013 will be inexpensive; a broader Phase IIb may eventually follow. Collaborations may generate milestones in 2013 if partners designate clinical candidates. This could give funding into 2014 before any BI-505 deal value, if partnered in 2013.
To Read the Entire Report Please Click on the pdf File Below.
January 2013 brought a clear safety and dose signal in the BI-505 Phase I for relapsed and refractory multiple myeloma (MM). In preclinical studies, BI-505 showed a tumour cell killing effect possibly by making myeloma cells susceptible to apoptosis. The Phase I was dose escalating with a safety end point. Interestingly but anecdotally, seven of 29 patients (24%) on extended dosing showed stable disease. BI-505 will progress to a small Phase IIa during 2013. BioInvent (BINV.ST) intends to partner BI-505
The one: BI-505 is crucial to current value
BI-505 is the remaining clinical programme from the January 2012 portfolio. Hence, gaining maximum value is important for investors. A deal by GenMab in August 2012 with J&J on a Phase I MM antibody, daratumumab, shows possible value. GenMab, a larger company, gained $55m upfront and $88m in equity with milestones and a 10%+ royalty. However, such Phase I deals are infrequent and BioInvent investors need to be prepared to fund BI-505 to add value by generating Phase II efficacy data.
Into two at 10: BI-505 progression to Phase II
BI-505 blocks the function of the cell surface adhesion molecule ICAM-1 (CD54). In the cancer literature, myeloid cells show cell-adhesion mediated drug resistance if attached to other cells. In BioInvent’s patent EP 2468775 (priority December 2006), ICAM blocking is claimed to cause apoptosis (cell suicide). The 35-patient dose escalation study in relapsed and refractory MM tested 11 dose stages of 0.0004mg/kg to 20mg/kg. BI-505 at 10mg/kg saturated the ICAM sites on bone marrow myeloma cells; this dose will be used for Phase II. Stable disease (based on M protein biomarker levels) was seen in 24% of the 29 patients who received extended dosing over 0.06mg/kg (level 6). The likelihood of success remains at 30%.
Valuation: Cash conservation to rebuild the portfolio
BioInvent had Q3 ytd cash of SEK153m with revenues of SEK 34m. Estimating year-end 2012 cash is difficult due to the actual H212 restructuring costs; SEK25-40m seems a probable range. The company needs to invest in BI-505, bring forward two other candidates into Phase I and support n-CoDeR. Operating cash costs in 2013 should be SEK75m. The small Phase IIa BI-505 study due to start sometime in 2013 will be inexpensive; a broader Phase IIb may eventually follow. Collaborations may generate milestones in 2013 if partners designate clinical candidates. This could give funding into 2014 before any BI-505 deal value, if partnered in 2013.
To Read the Entire Report Please Click on the pdf File Below.
Related Articles
Effortless Gains in the Stock Market May No Longer Be Realistic
By Charles Hugh Smith - Mar 24, 2023
3
Everyone wants a trend they can trade for effortless gains. That may no longer be realistic. Market commentators tend to focus on Bulls and Bears and Federal Reserve policies as...
The Obvious Mistake S&P 500 Bulls and Bears Keep Making
By Jani Ziedins - Mar 24, 2023
6
Thursday’s +0.3% finishing print in the S&P 500 fails to convey what a wild ride we took through the session. A huge opening rally erased Wednesday’s -1.7% slump as the whipsaw...
These 3%-5% Bank Yields Are a Steal
By Brett Owens - Mar 24, 2023
Is it time for us contrarians to “buy the dip” in bank stocks? We’re drowning in big bank-scare headlines. Silicon Valley Bank (SIVB) knuckled under in days,...
BioInvent International BI-505 First Clinical Data Now Available
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.